Neon Therapeutics

Initial results from Dana-Farber Cancer Institute personalized neoantigen vaccine published

Friday, July 7, 2017

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the publication of an article in Nature presenting initial feasibility, safety, immunogenicity and clinical outcomes for a personalized neoantigen vaccine in patients with adjuvant melanoma. The article entitled ‘An immunogenic personal neoantigen vaccine for patients with melanoma’ (DOI 10.1038/nature22991) demonstrates the validity of the neoantigen vaccine approach as an effective immunotherapy.

[Read More]

Vedantra, Neon Therapeutics partner to develop cancer vaccines

Wednesday, March 15, 2017

Vedantra Pharmaceuticals, an immunotherapy company focused on developing products for cancer and infectious disease, has announced a joint collaboration to explore cancer vaccine research with Neon Therapeutics, an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. The two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantra’s cutting edge albumin-binding, lymph node targeting amphiphile technology with Neon’s innovative capabilities in neoantigen vaccine research.

[Read More]

Neon Therapeutics appoints Dr. Richard Gaynor to president of R&D

Monday, November 7, 2016

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the appointment of Richard Gaynor, M.D., to president of research and development. Dr. Gaynor succeeds interim chief scientific officer Robert Tepper, M.D., a partner at Third Rock Ventures, who is continuing as a member of the company’s board of directors.

[Read More]